MLNM starts Velcade colorectal cancer Phase II

Millennium (MLNM) began an open-label U.S. Phase II trial of its Velcade bortezomib in up to 175 patients with refractory metastatic colorectal cancer. Patients will receive Velcade alone or in combin...